02
Nov
2009
Posted in I - Series A, Q - 3Q09, R - NORTH EAST, X - Autism, X - FragileX Syndrome, XX - MA
Seaside Therapeutics (Cambridge, MA) a clinical-stage biopharmaceutical company focused on autism and Fragile X syndrome, closed a $30M Series A financing. Participants were not identified.